Blauvelt A, Kimball AB, Augustin M, Okubo Y, et al. Efficacy and Safety of Mirikizumab in Psoriasis: Results from a 52-Week, Double-Blinded, Placebo-Controlled, Randomised Withdrawal, Phase III Trial (OASIS-1). Br J Dermatol 2022 Jul 6. doi: 10.1111/bjd.21743.
PMID: 35791755